Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Auderghem – page 154

1 992 clinical trials in Auderghem, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Auderghem at a glance
1 992
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 992 trials in Auderghem

Open in trial search

Monkeypox

Not recruiting

Study on Monkeypox Virus Disease: Effects of Tecovirimat in Patients with and without Antiviral Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tecovirimat
  • Sponsor:University Of Oxford

Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gilead Sciences Inc.

IgA nephropathy

Not recruiting

Study on Sibeprenlimab for Patients with IgA Nephropathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sibeprenlimab
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Study on the Effects of EDG-5506 for Adults and Adolescents with Becker Muscular Dystrophy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:EDG-5506
  • Sponsor:Edgewise Therapeutics Inc.

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Study on the Effects of JNJ-63733657 and Florquinitau F18 in Patients with Early Alzheimer's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Posdinemab
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Long-term Safety Study of Daratumumab with Drug Combination for Patients with Multiple Myeloma or Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Janssen Cilag International

Study on the Effects of Risdiplam in Adults with Spinal Muscular Atrophy Types 2 or 3 or with Up to 4 SMN2 Gene Copies

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Risdiplam
  • Sponsor:UZ Leuven

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Partial seizures

Not recruiting

Study on ENX-101 for Treating Focal Epilepsy in Patients Using 1 to 4 Antiseizure Medications

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:ENX-101
  • Sponsor:Engrail Therapeutics Inc.

Study on Atezolizumab for Patients with High-Risk Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Monkeypox

Not recruiting

Study on Tecovirimat for Treating Monkeypox in Patients with Confirmed Infection

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tecovirimat
  • Sponsor:Universitair Medisch Centrum Utrecht

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Auderghem

What the registry says about research in the country

01 Neoplasms

In Auderghem, researchers are concentrating on lung cancer, specifically Non‑Small Cell Lung Cancer and small cell lung cancer. The two active studies compare new immune‑targeted agents such as pumitamig and obrixtamig against established therapies like pembrolizumab and standard chemotherapy, aiming to improve overall survival and disease control.

  • Comparative efficacy of novel immunotherapies
  • Evaluation of survival benefit in advanced disease
  • Biomarker‑guided patient selection (e.g., DLL3 expression)
  • Combination regimens with checkpoint inhibitors

Both trials are actively recruiting, reflecting a growing commitment in Auderghem to advance treatment options for patients with aggressive lung cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.